The 10q25-26 region between the dinucleotide markers D10S587 and D10S216 is deleted in glioblastomas and, as we have recently shown, in low-grade oligodendrogliomas. We further re®ned somatic mapping on 10q23-tel and simultaneously assessed the role of the candidate tumor suppressor gene PTEN/MMAC1 in glial neoplasms by sequence analysis of eight low-grade and 24 high-grade gliomas. These tumors were selected for partial or complete loss of chromosome 10 based on deletion mapping with increased microsatellite marker density at 10q23-tel. Three out of eight (38%) low-grade and 3/24 (13%) high-grade gliomas exclusively target 10q25-26. We did not ®nd a tumor only targeting 10q23.3, and most tumors (23/32, 72%) showed large deletions on 10q including both regions. The sequence analysis of PTEN/MMAC1 revealed nucleotide alterations in 1/8 (12.5%) low-grade gliomas in a tumor with LOH at 10q21-qtel and in 5/21 (24%) high-grade gliomas displaying LOH that always included 10q23-26. Our re®ned mapping data point to the 10q25-26 region as the primary target on 10q, an area that also harbors the DMBT1 candidate tumor suppressor gene. The fact that we ®nd hemizygous deletions at 10q25-qtel in low-grade astrocytomas and oligodendrogliomas ± two histologically distinct entities of gliomas ± suggests the existence of a putative suppressor gene involved early in glial tumorigenesis.
The 10q25-26 region between the dinucleotide markers D10S587 and D10S216 is deleted in glioblastomas and, as we have recently shown, in low-grade oligodendrogliomas. We further re®ned somatic mapping on 10q23-tel and simultaneously assessed the role of the candidate tumor suppressor gene PTEN/MMAC1 in glial neoplasms by sequence analysis of eight low-grade and 24 high-grade gliomas. These tumors were selected for partial or complete loss of chromosome 10 based on deletion mapping with increased microsatellite marker density at 10q23-tel. Three out of eight (38%) low-grade and 3/24 (13%) high-grade gliomas exclusively target 10q25-26. We did not ®nd a tumor only targeting 10q23.3, and most tumors (23/32, 72%) showed large deletions on 10q including both regions. The sequence analysis of PTEN/MMAC1 revealed nucleotide alterations in 1/8 (12.5%) low-grade gliomas in a tumor with LOH at 10q21-qtel and in 5/21 (24%) high-grade gliomas displaying LOH that always included 10q23-26. Our re®ned mapping data point to the 10q25-26 region as the primary target on 10q, an area that also harbors the DMBT1 candidate tumor suppressor gene. The fact that we ®nd hemizygous deletions at 10q25-qtel in low-grade astrocytomas and oligodendrogliomas ± two histologically distinct entities of gliomas ± suggests the existence of a putative suppressor gene involved early in glial tumorigenesis.
Keywords: deletion mapping; chromosome 10q23.3 and 10q25-26; PTEN/MMAC1 Loss of heterozygosity (LOH) on chromosome 10 has frequently been found in a variety of human cancers, such as endometrial (Peier et al., 1995) , prostate (Gray et al., 1995) , bladder (Cappellen et al., 1997) , renal cell carcinoma (Morita et al., 1991) , NonHodgkin lymphomas (Speaks et al., 1992) , malignant meningiomas (Rempel et al., 1993) , melanomas (Herbst et al., 1994) and gliomas (Fults et al., 1990; Fujimoto et al., 1989; Rasheed et al., 1992; James et al., 1988; Steck et al., 1995) . Eighty to ninety per cent of malignant gliomas display large deletions on chromosome 10. Although somatic mapping has proven dicult to delineate speci®c regions of loss, 10q25-26 has consistently been suspected to harbor a tumor suppressor gene (Fults et al., 1993; Rasheed et al., 1995; Albarosa et al., 1996) . Recently, PTEN/MMAC1 on 10q23.3 has been proposed as a candidate tumor suppressor gene for gliomas and other neoplasms, clearly de®ning a second locus on 10q Steck et al., 1997) . This gene has also been shown to be involved in two rare inherited disorders, the Cowden and the Bannayan-Zonana syndrome . PTEN/MMAC1 encodes a protein tyrosine phosphatase, shares extensive homology to the cytoskeletal proteins tensin and auxilin, and has been shown to act either as positive or negative regulator during signal transduction, cell cycle progression, and cellular transformation (Tonks et al., 1996) , and is regulated by transforming growth factor b (Li and Sun, 1997) .
The more telomeric region on 10q25-26 between the dinucleotide markers D10S587 and D10S216 is involved in glioblastomas (Rasheed et al., 1995; Albarosa et al., 1996) , and in low-grade oligodendrogliomas, too, as we have recently shown (Maier et al., 1997) . The involvement of this very region in earlier tumor stages has also been described in endometrial carcinomas (Nagase et al., 1997) . We further re®ned somatic mapping on 10q in another seven low-grade gliomas (®ve astrocytomas and two mixed oligoastrocytomas). From the total number (n=86) of low-grade (n=14) and high-grade (n=72) gliomas which have been used for somatic mapping on chromosome 10, we selected eight low-grade (®ve astrocytomas, one mixed oligoastrocytoma, and two oligodendrogliomas) and 24 high-grade gliomas, which either displayed LOH at the PTEN/MMAC1 locus (n=23), selectively targeted 10q25-26 (n=6) or were of low-grade type without LOH on chromosome 10 (n=3), to assess the role of PTEN/MMAC1 in glial tumorigenesis by analysing the genomic sequence of this new candidate suppressor gene on 10q23.3. These tumors were selected for partial and complete LOH, since the biallelic inactivation of a tumor suppressor gene typically involves an intragenic change (nucleotide substitution, small insertion, or microdeletion) within one allele, combined with inactivation of the other allele through the loss of a large chromosomal region (Knudson, 1993) . Sequence analysis of PTEN/MMAC1 revealed nucleotide alterations in 1/8 (12.5%) lowgrade gliomas and in 5/21 (24%) high-grade gliomas. None of the 9/32 (28%) tumors that did not display LOH at the PTEN/MMAC1 locus showed sequence alterations of this gene. All mutated tumors displayed LOH at the PTEN/MMAC1 locus. These ®ndings suggest that PTEN/MMAC1 plays a role in glioma tumorigenesis. However, we ®nd partial somatic deletions to be more frequent on 10q25-26 in lowgrade and high-grade gliomas, suggesting that this region is the primary target in glioma tumorigenesis on chromosome 10q.
Tumor tissue and peripheral blood lymphocytes were obtained from 32 patients diagnosed with primary CNS tumors and were classi®ed according to the World Health Organization: 24 high-grade astrocytomas grade IV (glioblastoma multiforme) and eight low-grade gliomas grade II (one oligoastrocytoma, two oligodendrogliomas and ®ve astrocytomas). DNA from tumor specimens and lymphocytes was analysed for loss of heterozygosity (LOH) by ampli®cation of 31 diand tetranucleotide repeat-containing sequences using PCR and the conditions described (Merlo et al., 1994) . Primers for microsatellite markers were obtained from Research Genetics (Huntsville, AL). Primer sequences for PTENCA, a highly informative dinucleotide repeat marker at the 5' end of PTEN/MMAC1, were kindly provided by P Cairns and D Sidransky . For microsatellite analysis, one primer was labeled with T4-polynucleotide kinase (New England Biolabs) and g- ranged from 50 ± 628C. Products were separated using 7% polyacrylamide-formamide gel electrophoresis followed by autoradiography. For informative cases, allelic loss was scored if the radiographic signal of one allele was at least 50% less in tumor DNA as compared to the corresponding normal allele. For mutation screening of the candidate tumor suppressor gene PTEN/MMAC1, 50 ng of genomic DNA from primary tumors and blood lymphocytes was ampli®ed by PCR. Cycle sequencing was performed directly on PCR products using a nested sequencing primer end-labeled with g 32 P-ATP and the AmpliCycle TM Sequencing Kit (Perkin Elmer, Branchburg, NJ). The primer sequences for exons 1 ± 9 of PTEN/MMAC1 were kindly provided by R Parsons. The products of cycle sequencing were electrophoresed on standard 6% acrylamide gels followed by autoradiography. All mutations were con®rmed by a repeated analysis. Because of a relatively high admixture of non-neoplastic DNA, specimen GE31 was recut, and reextracted DNA was used to con®rm the codon 61 mutation in exon 3.
Our sequencing data of PTEN/MMAC1 combined with somatic mapping on chromosome 10q shows two distinct regions on 10q to be involved in glioma tumorigenesis. One region is de®ned by the candidate tumor suppressor gene PTEN/MMAC1 on 10q23.3. To study the role of this gene in primary gliomas by sequence analysis, we selected eight low-grade and 24 high-grade gliomas according to the following criteria: we included all tumors with partial deletions on chromosome 10q (six only targeting 10q25-26, two tumors targeting both 10q23.3 and 10q25-26), with complete LOH on chromosome 10 (one low-grade, 20 high-grade gliomas) and without LOH on chromosome 10 (three low-grade gliomas). We detected 5/21 (24%) sequence alterations in high-grade gliomas displaying LOH at the PTEN/MMAC1 locus (Table 1 and Figure  1b) . In GBM BS10, we detected a splicing junction variant in intron 4. In GBM BS7, we found a 3 bp deletion in exon 6 (delM198) (Figure 1b) . A 2 bp deletion at codon 88 in exon 5 (Y88frameshift) was detected in GBM LS971, leading to a truncated version of PTEN/MMAC1 at the protein level. In GBM BS11, we found two sequence alterations: a nonsense mutation in exon 7 (R233Opal) and a polymorphism in intron 3 (del T). In GBM BS54, a missense mutation was detected in exon 6 (R173H). In one (GE31) out of eight low-grade gliomas (12.5%), we found a missense mutation in a tumor that has LOH at 10q21-qtel, leading to an amino acid change from Histidine to Arginine at codon 61 in exon 3 (H61R) (Figure 1c) . This low-grade glioma has a relatively high admixture of non-neoplastic cells (or an intra-tumoral cell population without LOH on 10q), as visible on the weak signal of the mutated nucleotide. For this reason, we reassessed DNA from recut tumor tissue of the same patient which con®rmed the point mutation. The amino acid designated by this codon is conserved in the proteins tensin and auxilin which share extensive N-terminal sequence homology with PTEN/MMAC1, suggesting that this sequence alteration might be functionally relevant . Mutations in this large region of homology (+175 amino acids) might be functionally important to tumor suppression since mutations within this domain have been described by Steck et al and by Li et al. in their original reports. The fact that we detected a mutation in a low-grade astrocytoma (GE31) suggests that this candidate tumor suppressor gene might occasionally also contribute to earlier stages of tumorigenesis. Since the mutation rate as assessed by direct analysis of the genomic sequence of PTEN/MMAC1 in primary gliomas was found to be much lower than LOH at the PTEN/MMAC1 locus, we searched for alternative mechanisms of gene inactivation, that could be missed by direct sequence analysis. For example, homozygous deletions are technically dicult to exclude in primary tumor specimens. It has been shown that an apparently retained small region within a large hemizygous deletion can be reliably interpreted as a homozygous deletion in primary tumors (Cairns et al., 1995) . We therefore used a polymorphic STS marker that lies within PTEN/MMAC1 (PTENCA) to search for biallelic deletions. However, homozygous deletions could not be discerned in these tumors using this approach. In 17/32 gliomas displaying large hemizygous deletions always spanning the 10q23-qtel region (not considering the six tumors with mutations of PTEN/MMAC1 and the nine gliomas with retention of both alleles at the PTEN/MMAC1 locus), we could not observe a case with intragenic retention of both PTENCA alleles suspicious for a homozygous deletion. PTEN/MMAC1 could also be inactivated by transcriptional silencing due to aberrant methylation of the promoter as shown for the von Hippel-Lindau (VHL) gene (Herman et al., 1994) and for p16 INK4A . Whether this mechanism plays a role in gene inactivation of PTEN/MMAC1 remains to be investigated.
Our re®ned somatic deletion mapping of chromosome 10q which is based on four low-grade and four high-grade gliomas (Figure 2) shows that the 10q25-26 region is the primary target on 10q in these neoplasms. In addition to 62 previously mapped low-grade (n=7) and high-grade gliomas (n=55), we mapped another seven low-grade and 17 high-grade gliomas for LOH on chromosome 10 using the same approach as previously described (Maier et al., 1997) . Taken together, complete LOH of chromosome 10q was found in 64 gliomas (one WHO grade II, ®ve grade III, and 58 grade IV gliomas). To obtain these data, we used on average 16 polymorphic markers (s.d.+6.2, range 7 ± 31) per tumor sample; each tumor was covered on average with an informativity of 70% to prove complete LOH. Combining the data of these 86 primary gliomas, we obtained the following frequencies of LOH. In lowgrade gliomas: LOH spanning both areas (10q23.3 and 10q25-26) was detected in 2/14 (14%) tumors, LOH exclusively targeting 10q25-26 was found in 3/14 (22%) tumors, no LOH on chromosome 10 in 9/14 (64%) tumors; in high-grade gliomas: LOH spanning both areas (10q23.3 and 10q25-26) was detected in 64/72 (89%) tumors, LOH exclusively targeting 10q25-26 was found in 3/72 (4%) tumors, no LOH on chromosome 10 in 5/72 (7%) tumors. Not a single tumor was exclusively targeting the 10q23 region.
Previously, we demonstrated LOH in a speci®c lowgrade glioma subtype (oligodendroglioma) to be con®ned to 10q25-26 (Maier et al., 1997) . We extended this analysis now to another low-grade glioma subtype (astrocytoma WHO grade II) and to a low-grade glioma of mixed composition (oligoastrocytoma WHO grade II). In these tumors, we con®rmed the more telomeric deletion, as shown for astrocytoma WHO grade II GE74 (Figures 1a and 2) . The site of recombination does not point to PTEN/ MMAC1 as the target in this tumor. In addition, sequence analysis of PTEN/MMAC1 was wild-type for this low-grade glioma. Wild-type sequence of PTEN/ MMAC1 was also obtained for the mixed oligoastrocytoma WHO grade II, which displayed complete LOH on chromosome 10 (OAII 1046).
The frequency of hemizygous loss at the PTEN/ MMAC1 locus was 25% (2/8) in low-grade and 83% (20/24) in high-grade gliomas, as assessed by the most informative marker PTENCA (30/32=94% of samples were informative). All cases displaying LOH at the PTENCA locus were also hemizygously deleted in at least one of the¯anking loci (AFMA086WG9, D10S541 and D10S579). Of the 23 gliomas with LOH at the PTEN/MMAC1 locus (22 gliomas with LOH at PTENCA and tumor GBM LS971 with a noninformative PTENCA but loss at¯anking markers), sequence analysis of this gene revealed altogether six (26%) mutations in these 23 low-and high-grade gliomas with LOH at the PTEN/MMAC1 locus. This mutation rate in this study is similar to the one described in the original reports Steck et al., 1997) and does not explain the high rate of LOH on chromosome 10q.
Our re®ned mapping data points to the 10q25-26 region as the primary target on 10q, surrounded by the markers D10S209 and D10S587, a 7 cM region that also harbors DMBT1 which has recently been proposed as a candidate tumor suppressor gene for (Moschonas et al., 1996) . The marker PTENCA lies at the 5' end of PTEN/MMAC1 . * Denotes the locus of DMBT1 (Mollenhauer et al., 1997) . Black circles, LOH; white circles, retention of both informative alleles; hatched circles, not informative; S=shift, allelic expansion or deletion. Abbreviations: wt, wildtype; mut, mutated; histological classi®cation according to the WHO grading (A, astrocytoma; OG, oligodendroglioma; GBM, glioblastoma multiforme)
Two targets on chromosome 10q23-26 in gliomas D Maier et al medulloblastomas and glioblastomas (Mollenhauer et al., 1997) . Tumors OG BS40 and GBM LS946 point to a region slightly telomeric to the DMBT1 locus (D10S587-D10S216) (Figure 2 ). The fact that we ®nd hemizygous deletions at 10q25-26 in a signi®cant proportion of low-grade astrocytomas and oligodendrogliomas ± two histologically distinct entities of gliomas ± suggests the existence of a putative suppressor gene involved early in glial tumorigenesis.
